



28 June 2012

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

**cyclo**medica  
**molecula**r imaging  
**techneg**as

Cyclopharm Ltd  
ABN 74 116 931 250  
Bldg 75 Business & Technology Park  
New Illawarra Road  
Lucas Heights NSW 2234 Australia  
POB 350 Menai Central NSW 2234  
T 61 2 9541 0411  
F 61 2 9543 0960  
[www.cyclopharm.com.au](http://www.cyclopharm.com.au)

### **Cyclopharm Files Claim Against ANSTO**

On 4 April, 2012 Cyclopharm Limited (ASX: CYC) announced that the Productivity Commission found that Petnet Pty Ltd, the wholly owned subsidiary of the Government's nuclear agency ANSTO, is in ex ante breach of their competitive neutrality requirements in the sale of their nuclear pharmaceuticals used in Positron Emission Tomography (PET). Further to this announcement Cyclopharm now advises that it's wholly owned subsidiary, CycloPet Pty Limited, has commenced proceedings in the Federal Court of Australia against Petnet Pty Limited.

In the filing CycloPet Pty Ltd is claiming damages for breach of s52 of the Trade Practices Act, 1974 (C'th), s18 of the Australian Consumer Law, s46 of the Trade Practices Act, 1974 (C'th) and s46 of the Competition and Consumer Act, 2010 (C'th). The proceedings allege misleading and deceptive conduct and misuse of market power.

A Direction Hearing has been set by the Federal Court for 2 August 2012.

I look forward to updating shareholders as this case progresses.

James McBrayer  
**Managing Director, CEO and Company Secretary**

#### **Contact details:**

Mr James McBrayer  
Managing Director, CEO and Company Secretary  
Cyclopharm Limited  
T: +61 2 9541 0411

## **Background**

### **Cyclopharm Limited**

Cyclopharm is a radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes.

Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging / PET radiopharmaceuticals (used in cancer, brain and cardiac imaging). Our customers are nuclear medicine departments located within hospitals and clinics.

### **Technegas**

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,500°C. The resultant gaseous substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

### **Positron Emission Tomography (PET)**

PET radiopharmaceuticals target specific tissues / organs, concentrate there, and the attached radioisotope emits radiation, which is then detected by a PET or PET / CT gamma (collectively PET camera). These imaging modalities help physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed.

### **Macquarie University Hospital and the Macquarie University School of Advanced Medicine**

Macquarie University Hospital is a major medical precinct within the Macquarie University Research Park to complement the Allied Health teaching services offered by Macquarie University.

The Macquarie University Hospital is a state of the art facility that delivers health education and research on site.

### **Macquarie Medical Imaging**

Cyclopharm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide all imaging services on-site at the hospital. The new venture named Macquarie Medical Imaging ("MMI") represents a rare strategic opportunity to provide a fully aligned and integrated diagnostic, therapeutic and research platform. MMI offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients.

The combination of state of the art imaging equipment, a GE cyclotron located on the grounds of MUH, leading surgeons, clinicians and academics will ensure that MMI will become the leading centre of imaging excellence.